Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Other financing activities came in at $847000.0 in Q1 2026, down 82.58% YoY from $4.9 million in Q1 2025, and down 89.84% on a QoQ basis from $8.3 million in Q3 2025.
Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Other financing activities data on file, last reported at $847000.0 in Q1 2026.
- Quarterly Other financing activities fell 82.58% year-over-year to $847000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 17.06% YoY) and the FY2025 annual result came in at $9.2 million, changed N/A from the prior year.
- Other financing activities retreated to $847000.0 in Q1 2026, from $8.3 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $8.3 million in Q3 2025 to a low of -$4.0 million in Q2 2025.
- A 5-year average of $914000.0 and a median of $459000.0 in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities plunged 142.51% — and 2025, when it jumped 959.04%.
- Tracing XERS's Other financing activities over 5 years: stood at -$502000.0 in 2022, then fell by 2.99% to -$517000.0 in 2023, then rose by 11.22% to -$459000.0 in 2024, then soared by 1916.34% to $8.3 million in 2025, then slumped by 89.84% to $847000.0 in 2026.
- The last three Other financing activities figures came in at $847000.0 (Q1 2026), $8.3 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 600,000.00 |
| Jun 30, 2026 | 600,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Sep 30, 2025 | 8.34 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | -459,000.00 |
| Dec 31, 2024 | -459,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Dec 31, 2023 | -517,000.00 |
| Dec 31, 2023 | -517,000.00 |
| Jun 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 549,000.00 |
| Sep 30, 2022 | -502,000.00 |
| Sep 30, 2022 | -502,000.00 |